GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-18. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
== Musical style == In an interview with MTV in 2006, vocalist Taylor said that Come What(ever) May was a return to the roots of the band, stating it is "a lot more from the spirit of what the band started with in 1992". He noted that some songs were "very atmospheric" while others maintained "the hard rock and the heavy stuff". Jon Wiederhorn of MTV said that "for every thrash riff there's a tunefully grungy passage, for every flailing guitar line there's a rock-radio hook." When talking about the track "30/30-150", he said parts are "bludgeoning, barbed and heavy" while others are "soaring and triumphant" with the production of Raskulinecz helping to balance the album's heaviness with its radio-accessibility. Come What(ever) May's lyrics include themes of "pain, pleasure, happiness, and grief". The diversity in subjects is evident throughout the album; songs including "Come What(ever) May" were politically influenced while the track "Socio" is about "social anxiety attacks" that Taylor suffered. "Zzyzx Rd" is a love song written to Taylor's wife for helping him in his struggles against alcoholism and contemplation of suicide. "I've never written anything like that before, but it was very important for me to tell the world not only how much she saved me, but how much she means to me," said Taylor. Taylor said there is a common thread with the lyrics throughout the album, saying that they are "about never forgetting where you came from, who you are and why you do this."
Valve, the developers of Source and Half-Life 2, contacted Newman to suggest a commercial, standalone release of the mod through their digital distribution service Steam, which Newman initially rejected. Valve and Facepunch later struck a publishing agreement wherein Valve would release Garry's Mod onto Steam at a price of US$10, while the two companies would equally split profits. The last free version of Garry's Mod remained available for download, rechristened as the demo to the retail game. The standalone game was released on 29 November 2006. Despite the game no longer being a mod, Valve and Facepunch stuck with the "Garry's Mod" name, which Newman later cited as a mistake, stating that he should have called it "Sandbox" instead. Because Garry's Mod still required a separate Source-based game to function properly, a bundle including Garry's Mod and Valve's Counter-Strike: Source was released alongside. A port of the Windows version for Mac OS X was released on 23 September 2010. Support for Kinect, a full-body motion tracking peripheral, was added to the Windows version in December 2012. When Garry's Mod was moved over to Valve's SteamPipe content delivery system, completed on 5 June 2013, an experimental Linux client was also introduced. In 2025, an update to the game added popularly-used assets from Counter-Strike: Source and episodic content from Half-Life 2, addressing a majority of missing content issues found in community maps and caused by not having the aforementioned games installed.
(CH2CH2)O + PCl5 → Cl–CH2CH2–Cl + POCl3 Other dichloro derivatives of ethylene oxide can be obtained by combined action of sulfuryl chloride (SOCl2) and pyridine and of triphenylphosphine and carbon tetrachloride. Phosphorus trichloride reacts with ethylene oxide forming chloroethyl esters of phosphorous acid:
Efraim Halevy (Hebrew: אפרים הלוי; born in London, 2 December 1934); Israeli intelligence expert and diplomat; was director of Mossad and 3rd head of Israeli National Security Council; author of Man in the Shadows, covering Middle Eastern history since the late 1980s; nephew of Sir Isaiah Berlin; has written for The Washington Post, Jerusalem Post, Times of Israel, Haaretz, Foreign Affairs, Ynet News, The Forward Simon Hattenstone (born 29 December 1962 in Salford, England) journalist and writer; features writer and interviewer for The Guardian. He has also written or ghost-written a number of biographical books. Paula Heimann; (2 February 1899 – 22 October 1982), author, academic, psychiatrist and psychoanalyst who established phenomenon of countertransference as important tool of psychoanalytic treatment, publishing influential studies, texts, academic papers and monographs; member of British Psychoanalytical Society; author of monograph A contribution to the problem of sublimation and paper On counter-transference, presented at the Psychoanalytical Congress in 1949 in Zurich, led to rift with Kleinian group of analysts; later turned to the Independents group and was Margarete Mitscherlich's analyst; Alexander Mitscherlich also underwent training analysis with her. Margot Heinemann (18 November 1913 – 10 June 1992) was a British Marxist writer, drama scholar, and leading member of the Communist Party of Great Britain (CPGB).
Sources: en.wikipedia.org
The particular series of amino acids that form a protein is known as that protein's primary structure. This sequence is determined by the genetic makeup of the individual. It specifies the order of side-chain groups along the linear polypeptide "backbone". Proteins have two types of well-classified, frequently occurring elements of local structure defined by a particular pattern of hydrogen bonds along the backbone: alpha helix and beta sheet. Their number and arrangement is called the secondary structure of the protein. Alpha helices are regular spirals stabilized by hydrogen bonds between the backbone CO group (carbonyl) of one amino acid residue and the backbone NH group (amide) of the i+4 residue. The spiral has about 3.6 amino acids per turn, and the amino acid side chains stick out from the cylinder of the helix. Beta pleated sheets are formed by backbone hydrogen bonds between individual beta strands each of which is in an "extended", or fully stretched-out, conformation. The strands may lie parallel or antiparallel to each other, and the side-chain direction alternates above and below the sheet. Hemoglobin contains only helices, natural silk is formed of beta pleated sheets, and many enzymes have a pattern of alternating helices and beta-strands. The secondary-structure elements are connected by "loop" or "coil" regions of non-repetitive conformation, which are sometimes quite mobile or disordered but usually adopt a well-defined, stable arrangement. The overall, compact, 3D structure of a protein is termed its tertiary structure or its "fold".
== Treatment == Treatment of established disease may include medications to lower cholesterol, such as statins, blood pressure medication, or medications that decrease clotting, such as aspirin. Many procedures may also be carried out such as percutaneous coronary intervention, coronary artery bypass graft, or carotid endarterectomy. Medical treatments often focus on alleviating symptoms. However, measures that focus on reducing underlying atherosclerosis, rather than simply treating symptoms, are more effective. Non-pharmaceutical means are usually the first method of treatment, such as stopping smoking and practicing regular exercise. If these methods do not work, medicines are usually the next step in treating cardiovascular diseases and, with improvements, have increasingly become the most effective method over the long term. The key to more effective approaches is to combine different treatment strategies. In addition, for those approaches, such as lipoprotein transport behaviors, which have been shown to produce the most success, adopting more aggressive combination treatment strategies taken daily and indefinitely has generally produced better results, both before and especially after people are symptomatic.
Natural fibers often show promise as biomaterials in medical applications. Chitin is notable in particular and has been incorporated into a variety of uses. Chitin based materials have also been used to remove industrial pollutants from water, processed into fibers and films, and used as biosensors in the food industry. Chitin has also been used several of medical applications. It has been incorporated as a bone filling material for tissue regeneration, a drug carrier and excipient, and as an antitumor agent. Insertion of foreign materials into the body often triggers an immune response, which can have a variety of positive or negative outcomes depending on the bodies response to the material. Implanting something made from naturally synthesized proteins, such as a keratin based implant, has the potential to be recognized as natural tissue by the body. This can lead either to integration in rare cases where the structure of the implant promotes regrowth of tissue with the implant forming a superstructure or degradation of the implant in which the backbones of the proteins are recognized for cleavage by the body.
Nobelium (102No) is a synthetic element, and thus a standard atomic weight cannot be given. Like all synthetic elements, it has no stable isotopes. The first isotope to be synthesized (and correctly identified) was 254No in 1966. There are fourteen known radioisotopes, which are 248No to 260No and 262No, and many isomers. The longest-lived isotope is 259No with a half-life of 58 minutes. The longest-lived isomer is 251m1No with a half-life of 1.02 seconds.
== Side effects == Rasburicase administration can cause anaphylaxis (incidence unknown); methemoglobinemia may occur in susceptible individuals such as those with G6PDH deficiency due to the production of hydrogen peroxide in the urate oxidase reaction. Testing patients for G6PDH deficiency prior to starting a course of rasburicase has been recommended.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.